Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

Opinion
Video

In this program, Sai-Hong Ou, MD, PhD, discusses biomarker testing for precision medicine in non-small cell lung cancer, emphasizing the importance of both tissue and blood-based genotyping, and the need for a complementary approach due to potential limitations in detecting targetable mutations.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
4 experts in this video
4 experts in this video
Related Content
No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC

Roman Fabbricatore
November 24th 2025
Article

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC

Tim Cortese
November 20th 2025
Article

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

FDA Approves Sevabertinib in Non-Squamous NSCLC

Tim Cortese
November 19th 2025
Article

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

EU Approves Subcutaneous Pembrolizumab in All Approved Indications

Roman Fabbricatore
November 19th 2025
Article

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.